Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial ++++++

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial Open Access https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00507-0/fulltext?dgcid=hubspot_email_conferencealerts_acc25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--at_a_Gzf_NtThFkDUmRzjxfm8j0GeemF-GvisRpYLkoHieB-QA7SjHuQlbNGKKNzu02AnYRtMkbHttRUE6VK5YgPE5g&_hsmi=354064752&utm_content=354064752&utm_source=hs_email Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial Free with registration until Apr 8, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00450-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_acc25&_hsenc=p2ANqtz-_B9vB-FbHDMQyY2XdKzSfF1DbuAgQzTcbhVednSv0wBBFEHh-6mc5srBYnNjFzS3SucgtGmAFR-n7B4hiWIAmdl3eqMQ&_hsmi=354064752&utm_content=354064752&utm_source=hs_email Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial Free with registration until Apr 8, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00505-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_acc25&_hsenc=p2ANqtz-8VSxQ7mGf-JzbJkcT40vaOyns6hlHs0J2f5de5VvC12vy4He38mzHY-vyGBw9acA9gjehTKa7Zx-do47i6YAtizNBBWQ&_hsmi=354064752&utm_content=354064752&utm_source=hs_email Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non‑inferiority trial Free with registration until Apr 8, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00504-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_acc25&_hsenc=p2ANqtz-9WHMQ6rRdXStP36UUFGZXN0DYhqjtrHNpf3K6Dx3t5KfvC8RAMRAA8TxvluMBXQIFFsW6vY3zy6T0Ibd5bqkATi-gZ_A&_hsmi=354064752&utm_content=354064752&utm_source=hs_email Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial Free with registration until Apr 8, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00509-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_acc25&_hsenc=p2ANqtz-8PuuVsRZjEZdaFHQIMyb5G5G4Miqm9DGhYCaNbaD0vTMHDeviFLmn-XivQ6eBiKSuVSyiIkivphEw0SP9NiN39LfuPew&_hsmi=354064752&utm_content=354064752&utm_source=hs_email Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial Free with registration until Apr 8, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00449-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_acc25&_hsenc=p2ANqtz-86pdGppm7Z5h0v6R8jzVj3OJhtcNwIdjAM1JNGHOsDzMw6xOYpnec5tSD_IG-pkjY6M1YInVlLsXcS70JAqblIKqACjQ&_hsmi=354064752&utm_content=354064752&utm_source=hs_email